HIV-1 conserved immunogen-derived peptide-Human Leukocyte Antigen class I complex (HIVconsv-HLA-I complex)

The HIV-1 conserved immunogen-derived peptide-Human Leukocyte Antigen class I complex (HIVconsv-HLA-I) is a molecular assembly consisting of highly conserved HIV-1 protein fragments bound within the peptide-binding groove of human MHC class I molecules. The HIVconsv immunogen is a chimeric protein incorporating the most stable and functionally essential regions of the HIV-1 proteome, such as Gag, Pol, Vif, and Env, across multiple viral clades (Létourneau et al., 2007, PLoS ONE). These complexes are presented on the surface of infected cells or professional antigen-presenting cells, where they are recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (CTLs) (Hanke, 2019, Expert Rev Vaccines). This recognition triggers the destruction of infected cells and the secretion of antiviral cytokines, forming a critical component of the cellular immune response against HIV-1. Therapeutic interventions, primarily vaccines using viral vectors like Chimpanzee Adenovirus (ChAdOx1) or Modified Vaccinia virus Ankara (MVA), are designed to prime and boost T cells specific to these conserved pMHC complexes (Borthwick et al., 2014, Mol Ther). Because the peptides are derived from conserved regions, this target aims to overcome the high mutational diversity of HIV-1 and provide broad protection across different viral strains. The effectiveness of this target is highly dependent on the host's HLA genotype, as different HLA alleles have varying affinities for specific HIVconsv-derived peptides (Rosario et al., 2010, Eur J Immunol).

Other names

HIVconsv-pMHC complexHIVconsv-HLA complexConserved HIV-1 epitope-HLA-I complexpMHC-I complex

Induction of cytotoxic CD8+ T-cell responses through the recognition of conserved HIV-1 epitopes presented by HLA class I molecules on the surface of cells.